Enveda has raised a $311 million series E crossover round, extending a financing run that also included a $130 million series C in November 2024 and $150 million in series D funds in September 2025. The company said the new money will help move three medicines deeper into development, with CEO Viswa Colluru saying the goal is to build a company that can carry its own drugs from discovery through late-stage development.
Across its life to date, Enveda said it has raised more than $845 million. The company framed the latest round as support for a broader operating model, not just a discovery engine, with Colluru arguing that AI can help deliver medicines faster and at lower cost than the industry has come to accept.
The pipeline Enveda is financing
The near-term use of proceeds is concentrated on three internal programs. ENV-294, an oral small molecule, produced phase 1b data in July showing a mean 68% reduction in eczema area and severity by Day 28, deepening to 85% by Day 42, according to Fierce Biotech. Enveda is already running phase 2a trials in atopic dermatitis and asthma.
ENV-308 is Enveda’s oral obesity-related program designed to replicate the effects of the post-exertion hormone N-lactoyl-phenylalanine while remaining suitable for daily dosing. The company has described it as an “exercise in a tablet” candidate and is testing whether it can help people maintain weight loss after stopping GLP-1s. BioSpace reported that ENV-308 demonstrated tolerability in a Phase 1 trial that read out in August, while Fierce Biotech noted phase 1 data in healthy volunteers last month.
The third named program, ENV-6946, is in phase 1 for inflammatory bowel disease. Enveda said the series E proceeds will support moving that asset through mid-stage development.
Why this round matters
The financing is a sign that capital remains available for AI-linked biotech companies when the story is anchored in assets that have already entered the clinic. Enveda said it has developed 17 candidates to date, with three already in human testing, and expects to have enough money left over from the round to progress other candidates into the clinic for inflammatory and metabolic disorders.
That distinction matters. Investors in this market have often demanded proof that platform companies can translate computational claims into drug programs with clinical signals. Enveda now has early human readouts on two molecules and a third asset in phase 1, giving backers a more asset-specific basis for underwriting the next step.
The round was led by Catalio Capital Management, with participation from T. Rowe Price Investment Management, Surveyor Capital, Durable Capital Partners, ICONIQ and Lightspeed. Enveda also said part of the capital will go toward building up its PRISM AI platform, but the strategic signal is that the company is now asking investors to fund execution in development, not just discovery.
